Table 1.
Baseline demographic and laboratory data of the study population.
| n | Control (n = 34) | Alcohol-associated liver disease (n = 58) | Nonalcoholic fatty liver disease (n = 78) | p value | |
|---|---|---|---|---|---|
| Gender [male], n [%] | 170 | 20 (58.8%) | 40 (69.0%) | 38 (48.7%) | 0.061 |
| Age [years] | 170 | 33.5 [30.6;44.9] | 43.5 [36.2;53.0] | 55.6 [43.3;63.4] | 0.001 |
| BMI [kg/m2 | 170 | 21.1 [20.0;24.1] | 24.2 [22.0;27.5] | 30.1 [27.5;33.5] | <0.001 |
| AST [IU/L] | 160 | 19.0 [16.0;25.0] | 53.5 [29.0;101] | 35.0 [28.0;52.0] | <0.001 |
| ALT [IU/L] | 160 | 13.0 [9.00;15.0] | 46.5 [24.2;87.5] | 48.0 [33.0;78.0] | <0.001 |
| GGT [IU/L] | 160 | 16.0 [11.0;20.4] | 108 [42.0;289] | 72.0 [46.0;125] | <0.001 |
| AP [IU/L] | 158 | 55.5 [49.6;62.1] | 75.0 [60.0;88.0] | 75.0 [65.0;94.0] | 0.001 |
| Bilirubin [mg/dL] | 158 | 0.30 [0.15;0.58] | 0.50 [0.30;0.60] | 0.50 [0.40;0.80] | 0.029 |
| Albumin [g/dL] | 157 | 4.40 [4.40;4.50] | 4.60 [4.30;4.93] | 4.40 [4.20;4.60] | 0.004 |
| INR | 148 | 1.00 [1.00;1.00] | 0.98 [0.91;1.03] | 1.00 [0.90;1.00] | 0.599 |
| Creatinine [mg/dL] | 159 | 0.81 [0.71;1.00] | 0.81 [0.72;0.87] | 0.85 [0.71;1.02] | 0.378 |
| Platelets [109/L] | 150 | 240 [230;264] | 231 [171;277] | 217 [181;278] | 0.496 |
| CAP [dB/m] | 99 | 195 [184;200] | 310 [268;330] | 280 [261;314] | <0.001 |
| Stiffness [kPa] | 146 | 4.60 [4.00;5.35] | 5.50 [4.12;6.68] | 6.20 [4.80;13.0] | 0.003 |
Values are presented as median and upper and lower quartiles in brackets. The number of subjects for which data were available is indicated in the first column. Continuous variables were compared using the Wilcoxon-Whitney-Mann rank-sum test. Categorical variables were compared using the Pearson’s Chi-squared test. Bold font indicates statistical significance (p < 0.05). ALT, alanine aminotransferase; AP, alkaline phosphatase; AST, aspartate aminotransferase; BMI, body mass index; CAP, controlled attenuation parameter; GGT, gamma-glutamyltransferase; INR, international normalized ratio.